Ratings SIGA Technologies, Inc.

Equities

SIGA

US8269171067

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
9.44 ^USD	+1.34%		+9.26%	+68.57%

04-01	SIGA Technologies to Drive International Promotion for Oral TPOXX in Amended Deal With Meridian Medical	MT
04-01	SIGA Technologies, Inc. Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX	CI

Summary

According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SIGA TECHNOLOGIES, INC.	+68.57%	671M	C-
ELI LILLY AND COMPANY	+29.68%	681B	C+
NOVO NORDISK A/S	+20.44%	556B	B
JOHNSON & JOHNSON	-4.35%	361B	C+
MERCK & CO., INC.	+17.65%	325B	B-
ABBVIE INC.	+3.77%	285B	C+
ASTRAZENECA PLC	+14.57%	235B	B+
NOVARTIS AG	+4.34%	199B	B-
ROCHE HOLDING AG	-11.04%	189B	A+
PFIZER, INC.	-3.79%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes